Literature DB >> 9051146

Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma.

T Zaccheo1, D Giudici, E di Salle.   

Abstract

BACKGROUND: Turosteride (FCE 26073) is a new, potent, and selective 5 alpha-reductase inhibitor. We have investigated its effect on tumor growth, organ weight, and serum hormone levels in rats bearing the androgen sensitive Dunning R3327 prostatic carcinoma.
METHODS: Animals with tumor diameters of 0.5-1.5 cm were treated for 9 weeks with turosteride (50 and 200 mg/kg/day, 6 days a week, orally), flutamide (25 mg/kg/day, 6 days a week, orally), and leuprolide (300 micrograms/rat, every 3 weeks, subcutaneously) or they were castrated.
RESULTS: Turosteride was ineffective at the dose of 50 mg/kg/day, whereas at 200 mg/kg/ day it significantly decreased tumor growth by 45%. Flutamide and leuprolide were highly effective in reducing tumor growth (70 and 77%), although their effect was slightly lower than that of castration (85%). A significant reduction of ventral prostate weight occurred in rats treated with turosteride at 50 and 200 mg/kg/day (53% and 60%). In contrast to leuprolide and castration, the inhibitory effect of turosteride on tumor growth and prostate weight was not associated to any decrease in serum testosterone.
CONCLUSIONS: Turosteride has antitumor activity on Dunning prostatic tumor growth and its role in prostatic cancer treatment is worthy of further investigation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9051146     DOI: 10.1002/(sici)1097-0045(19970201)30:2<85::aid-pros3>3.0.co;2-j

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  3 in total

1.  The potential for prostate cancer chemoprevention.

Authors:  Otis W Brawley
Journal:  Rev Urol       Date:  2002

2.  Does the level of prostate cancer risk affect cancer prevention with finasteride?

Authors:  Ian M Thompson; Catherine M Tangen; Howard L Parnes; Scott M Lippman; Charles A Coltman
Journal:  Urology       Date:  2008-05       Impact factor: 2.649

Review 3.  Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

Authors:  Steven J Hudak; Javier Hernandez; Ian M Thompson
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.